Aeterna Zentaris

AEZS

2.41

+0.01

+0.4%

Please Login or Register

Login|Register FREE

Stock Price
Open: 2.44
Prev. Close: 2.40
Low/Hi: 2.36 - 2.44
52-Week: 0.78 - 3.75
Volumes
Equity: 165,889
90-Day Avg: 711,493
Option: 20
90-Day Avg: 112
Volatility
Todays Stock Vol: 45.4
20-Day (HV): 90.1
52-Week (HV): 86.6
30-Day IV: 70.5 -7.4
IV Pct Rank: 10% Subdued
Fundamental
Div. Yield:
Earnings: 22-Mar (Est.)
P/E Ratio:
Market Cap: 39.5 M
Short Int Pct: 0.0%
Pct Held By Inst.: 1.9%
Stock Info
Type: Common
Sector: Healthcare
Industry: Biotechnology

AEZS Company Events

Upcoming Events
Event Event Date Location Info
No Upcoming Events
Past Events
Event Event Date Location Info
2017 Marcum MicroCap Conference Jun 16, 9:30 AM
Annual Meeting of Shareholders May 9, 10:00 AM
2017 Genitourinary Cancers Symposiums Feb 16, 11:30 AM
2nd Annual Disruptive Growth & Healthcare Conference Feb 16, 2017
2017 BIO CEO & Investor Conference Feb 13, 2017
Aegis Capital Corp. 2016 Growth Conference Sep 22, 1:00 PM
i

Chief Executive Officer, David Dodd, will present a corporate overview.

Rodman & Renshaw 18th Annual Global Investment Conference Sep 12, 9:35 AM
i

Company's President and Chief Executive Officer, David Dodd, will present a corporate overview.

Annual Meeting of Shareholders May 10, 2016 New York, New York 1
18th Annual BIO CEO & Investor Conference Feb 8, 2016 - Feb 9, 2016 New York City
i

Chairman, President and Chief Executive Officer David A. Dodd will parMr. Dodd will update participants on the status of the Companys two Phase 3 clinical trials and will continue the Companys efforts to secure additional partners for the development of Zoptrex, which if approved by the FDA, would be the first systemic therapy for the treatment of advanced and recurrent endometrial cancer, and for Macrilen, which if approved by the FDA, would be the first orally administered drug indicated for the evaluation of adult growth hormone deficiency (AGHD). The Company continues to actively seek opportunities to in-license and acquire products for US commercialization, consistent with its goal of becoming a growth-oriented specialty biopharmaceutical company by pursuing successful development and commercialization of its product portfolioticipate.

Special Meeting of Shareholders Nov 16, 2015
i

for shareholders of record on October 14, 2015 to consider a special resolution authorizing the consolidation of the issued and outstanding common shares of the Corporation at a consolidation ratio of between 8-for-1 and 100-for-1 (the "Share Consolidation") and that the Notice of Special Meeting of Shareholders and Management Information Circular (the "Circular") have been mailed to shareholders

Rodman & Renshaw 17th Annual Global Investment Conference Sep 9, 2015 St. Regis Hotel in New York City
i

Chief Financial Officer, Dennis Turpin, will be presenting

Rodman & Renshaw 17th Annual Global Investment Conference Sep 9, 2015 Library Room (2nd floor) of the St. Regis Hotel in New York City .
Canaccord Genuity 35th Annual Global Growth Conference Aug 12, 2015 in the Melbourne Room of the Intercontinental Hotel in Boston.

Wait, Before You Leave...

Want to Know More About AEZS Earnings?

Receive your FREE email to get Wall Street expected earnings moves and daily upcoming earnings alerts!
Market Chameleon